GlycoMimetics (GLYC) Q2 2024 earnings summary

Executive summary

• GlycoMimetics is a late clinical-stage biotech focused on cancer and inflammatory diseases, with lead candidate uproleselan for AML not meeting the primary endpoint in a Phase 3 trial; a strategic review and major restructuring are underway.

• Following FDA feedback, an additional clinical trial is required for uproleselan, prompting an 80% workforce reduction and a focus on maximizing shareholder value through potential strategic transactions.

Financial highlights

• Net loss for Q2 2024 was $10.1 million, up from $8.3 million in Q2 2023; six-month net loss was $20.8 million, compared to $18.6 million year-over-year.

• Cash and cash equivalents were $22.4 million as of June 30, 2024, down from $41.8 million at year-end 2023.

• No revenue was recognized from product sales or milestones in the period; all revenue to date has been from upfront and milestone payments under license agreements.

• Research and development expenses rose 54% year-over-year for Q2, mainly due to uproleselan manufacturing and formulation costs.

• General and administrative expenses decreased 16% year-over-year for Q2, primarily due to lower personnel-related costs.

Outlook and guidance

• Current cash resources are expected to fund operations into Q2 2025; further capital or strategic transactions are needed to extend runway.

• The company is not pursuing further development of uproleselan without additional funding and is exploring mergers, asset sales, or other alternatives.